GSK plc (GSK,GSK.L) announced that China's National Medical Products Administration has approved Exdensur or depemokimab as add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in adult and paediatric patients aged 12 years and older. The approval is based on data from the SWIFT-1 and SWIFT-2 phase III trials.
Kaivan Khavandi, SVP, Global Head, Respiratory, Immunology & Inflammation R&D, GSK, said: "With Exdensur now approved in several major markets, we are focused on transforming the treatment paradigm in severe asthma."
At last close, GSK shares were trading at 2,049.00 pence.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.